191 related articles for article (PubMed ID: 26197890)
1. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature.
Jia N; Cormack FC; Xie B; Shiue Z; Najafian B; Gralow JR
BMC Cancer; 2015 Jul; 15():535. PubMed ID: 26197890
[TBL] [Abstract][Full Text] [Related]
2. Pamidronate-induced kidney injury in a patient with metastatic breast cancer.
Nagahama M; Sica DA
Am J Med Sci; 2009 Sep; 338(3):225-8. PubMed ID: 19581797
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of collapsing focal segmental glomerulosclerosis.
Raja R; Nada R; Yadav AK; Kumar A; Goyal A; Kumar V; Rathi M; Kohli HS; Gupta KL; Sakhuja V; Jha V
Ren Fail; 2016 Jul; 38(6):894-8. PubMed ID: 27266801
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
5. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
[TBL] [Abstract][Full Text] [Related]
6. Podocyte injury associated glomerulopathies induced by pamidronate.
Barri YM; Munshi NC; Sukumalchantra S; Abulezz SR; Bonsib SM; Wallach J; Walker PD
Kidney Int; 2004 Feb; 65(2):634-41. PubMed ID: 14717935
[TBL] [Abstract][Full Text] [Related]
7. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
[TBL] [Abstract][Full Text] [Related]
8. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
Sauter M; Jülg B; Porubsky S; Cohen C; Fischereder M; Sitter T; Schlondorff D; Gröne HJ
Am J Kidney Dis; 2006 Jun; 47(6):1075-80. PubMed ID: 16731304
[No Abstract] [Full Text] [Related]
9. Nephrotic syndrome induced by pamidronate.
ten Dam MA; Hilbrands LB; Wetzels JF
Med Oncol; 2011 Dec; 28(4):1196-200. PubMed ID: 20865462
[TBL] [Abstract][Full Text] [Related]
10. Acute kidney injury in a patient with nephrotic syndrome due to focal segmental glomerular nephritis induced by a single oral administration of high-dose bisphosphonate (minodronate).
Komada T; Morishita Y; Kitamura M; Iwazu K; Numata A; Kobayashi T; Yamamoto H; Akimoto T; Saito O; Ando Y; Takemoto F; Muto S; Yumura W; Kusano E
Intern Med; 2013; 52(12):1383-7. PubMed ID: 23774552
[TBL] [Abstract][Full Text] [Related]
11. Reversibility of pamidronate-associated glomerulosclerosis.
Shreedhara M; Fenves AZ; Benavides D; Stone MJ
Proc (Bayl Univ Med Cent); 2007 Jul; 20(3):249-53. PubMed ID: 17637879
[TBL] [Abstract][Full Text] [Related]
12. Ibandronate: its role in metastatic breast cancer.
Cameron D; Fallon M; Diel I
Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
[TBL] [Abstract][Full Text] [Related]
13. Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate.
Pascual J; Torrealba J; Myers J; Tome S; Samaniego M; Musat A; Djamali A
Osteoporos Int; 2007 Oct; 18(10):1435-8. PubMed ID: 17404782
[TBL] [Abstract][Full Text] [Related]
14. Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.
Pivot X; Lortholary A; Abadie-Lacourtoisie S; Mefti-Lacheraf F; Pujade-Lauraine E; Lefeuvre C; Letessier S; Morvan P; Dür C; Frimat L
Breast; 2011 Dec; 20(6):510-4. PubMed ID: 21727006
[TBL] [Abstract][Full Text] [Related]
15. Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants.
Swaminathan S; Lager DJ; Qian X; Stegall MD; Larson TS; Griffin MD
Nephrol Dial Transplant; 2006 Sep; 21(9):2607-14. PubMed ID: 16705026
[TBL] [Abstract][Full Text] [Related]
16. Nephrotic syndrome with acute kidney injury due to focal segmental glomerulosclerosis following long-term treatment with minodronate.
Morinishi T; Nawata A; Konishi R; Ono E; Takaori K; Maeda S
CEN Case Rep; 2022 Feb; 11(1):120-125. PubMed ID: 34455572
[TBL] [Abstract][Full Text] [Related]
17. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
[TBL] [Abstract][Full Text] [Related]
18. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis.
Gossmann J; Scheuermann EH; Porubsky S; Kachel HG; Geiger H; Hauser IA
Transpl Int; 2007 Jun; 20(6):558-62. PubMed ID: 17433091
[TBL] [Abstract][Full Text] [Related]
19. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
20. Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
Miura N; Mizuno N; Aoyama R; Kitagawa W; Yamada H; Nishikawa K; Imai H
Clin Exp Nephrol; 2009 Feb; 13(1):85-8. PubMed ID: 18754075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
